Eagle Pharmaceuticals Inc.

42.62-1.65-3.73%Vol 78.47K1Y Perf -19.16%
Apr 19th, 2021 16:00 DELAYED
BID42.57 ASK42.73
Open43.97 Previous Close44.27
Pre-Market- After-Market42.62
 - -  - -%
Target Price
48.00 
Analyst Rating
Moderate Buy 2.33
Potential %
12.62 
Finscreener Ranking
★★★★+     56.48
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★     57.33
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★★+     64.13
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap563.31M 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
31.20 
Earnings Date
10th May 2021

Today's Price Range

42.0744.00

52W Range

36.4856.16

5 Year PE Ratio Range

9.10429.70

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
1.16%
1 Month
-5.92%
3 Months
-11.69%
6 Months
-8.30%
1 Year
-19.16%
3 Years
-22.42%
5 Years
13.62%
10 Years
-

TickerPriceChg.Chg.%
EGRX42.62-1.6500-3.73
AAPL134.840.68000.51
GOOG2 302.404.64000.20
MSFT258.74-2.0000-0.77
XOM56.48-0.1800-0.32
WFC43.880.04000.09
JNJ162.690.45000.28
FB302.24-3.9400-1.29
GE13.460.07000.52
JPM152.65-0.6500-0.42
Financial StrengthValueIndustryS&P 500US Markets
4.10
4.40
0.14
0.20
9.80
Leverage Ratio 1.40
ProfitabilityValueIndustryS&P 500US Markets
75.80
9.40
12.10
19.70
11.09
RevenueValueIndustryS&P 500US Markets
141.78M
10.73
-3.64
17.83
Earnings HistoryEstimateReportedSurprise %
Q04 2020-1.420.60142.25
Q03 20200.020.512.45K
Q02 2020-0.32-0.0293.75
Q01 20200.220.4186.36
Q04 20190.070.18157.14
Q03 20190.01-0.05-600.00
Q02 20190.310.4854.84
Q01 20190.210.62195.24
Earnings Per EndEstimateRevision %Trend
3/2021 QR0.20164.52Positive
6/2021 QR0.27237.50Positive
12/2021 FY1.20300.00Positive
12/2022 FY2.77--
Next Report Date10th May 2021
Estimated EPS Next Report0.20
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume78.47K
Shares Outstanding13.22M
Trades Count1.51K
Dollar Volume5.71M
Avg. Volume123.00K
Avg. Weekly Volume99.32K
Avg. Monthly Volume122.24K
Avg. Quarterly Volume123.53K

Eagle Pharmaceuticals Inc. (NASDAQ: EGRX) stock closed at 42.62 per share at the end of the most recent trading day (a -3.73% change compared to the prior day closing price) with a volume of 78.57K shares and market capitalization of 563.31M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 108 people. Eagle Pharmaceuticals Inc. CEO is Scott L. Tarriff.

The one-year performance of Eagle Pharmaceuticals Inc. stock is -19.16%, while year-to-date (YTD) performance is -8.48%. EGRX stock has a five-year performance of 13.62%. Its 52-week range is between 36.48 and 56.16, which gives EGRX stock a 52-week price range ratio of 31.20%

Eagle Pharmaceuticals Inc. currently has a PE ratio of 50.90, a price-to-book (PB) ratio of 3.15, a price-to-sale (PS) ratio of 4.13, a price to cashflow ratio of 12.30, a PEG ratio of 2.32, a ROA of 4.52%, a ROC of 2.92% and a ROE of 6.29%. The company’s profit margin is 11.09%, its EBITDA margin is 12.10%, and its revenue ttm is $141.78 Million , which makes it $10.73 revenue per share.

Of the last four earnings reports from Eagle Pharmaceuticals Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.20 for the next earnings report. Eagle Pharmaceuticals Inc.’s next earnings report date is 10th May 2021.

The consensus rating of Wall Street analysts for Eagle Pharmaceuticals Inc. is Moderate Buy (2.33), with a target price of $48, which is +12.62% compared to the current price. The earnings rating for Eagle Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Eagle Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Eagle Pharmaceuticals Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 10.98, ATR14 : 2.04, CCI20 : 37.95, Chaikin Money Flow : -0.03, MACD : -1.04, Money Flow Index : 48.12, ROC : 2.11, RSI : 49.58, STOCH (14,3) : 60.17, STOCH RSI : 0.36, UO : 53.56, Williams %R : -39.83), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Eagle Pharmaceuticals Inc. in the last 12-months were: Scott L. Tarriff (Option Excercise at a value of $273 945), Steven B. Ratoff (Option Excercise at a value of $10 343)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (33.33 %)
1 (33.33 %)
1 (33.33 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (66.67 %)
2 (66.67 %)
2 (66.67 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.33
Moderate Buy
2.33
Moderate Buy
2.33

Eagle Pharmaceuticals Inc.

Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development, and under review for approval by the Food and Drug Administration.

CEO: Scott L. Tarriff

Telephone: +1 201 326-5300

Address: 50 Tice Boulevard, Woodcliff Lake 07677, NJ, US

Number of employees: 108

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

53%47%

Bearish Bullish

63%37%

Bearish Bullish

56%44%

News

Stocktwits